Medivolve Inc MEDVF

Medivolve Webinar Summary – April 15th 2021 (Try This)

[Sarb99]

Posted by BrownShugguh on CEO
 
Collection Sites:
 

1. March numbers were 20,576 tests. Additional tests were done through Besser Brands, which is a franchiser operating 8 locations in Florida. Exact number not known.
2. Stability of testing demand. April is consistent with March.
3. Expanding in testing – AditxtScore (will talk about later)
4. Lots of work in B2B (business to business) to take tests to them.
5. Worked with an independent film production company. Were able to test all employees for all employees’ multiple times a day. Able to deliver PCR tests in less than 24 hrs.
6. Working with retail offerings through McDade and Associates (https://www.mcdadeassociates.com). Big company – reps vendors like Arizona Beverages, Lil Drug Store, Castrol, Gorilla Glue.
7. B2B is big focus
8. HRSA program. It’s a government run program for free PCR tests for undocumented and uninsured. (Known)

 
 
Vaccine Program:
 

1. Terminated the Nevada pharmacy deal (probably in DD)
2. In discussion in some opportunities in California – this ties in nicely with Telehealth.
3. They can gain access to CalVax license opportunity.
4. Still very active in pursuing the opportunities in California. They want to get to rural and underserved population.
5. JNJ issues have been a setback. Doug thinks the setback will be fine in a short period of time.
6. JNJ has administered 7M vaccines with only 6 cases.
7. Doug says FDA is taking precautionary step to understand the issues.
8. Thinks if they suspend JNJ, it will bring more problems.
9. JNJ is a perfect vaccine for anyone operating in pharmacy due to ease to ship and store and is ONE shot.
10. JNJ is good to get out to access underserved and rural communities.
11. Doug says they are continuing to pursue allocations of Moderna Vaccines. Though they do believe they will get opportunity with the JNJ vaccine after FDA approved readministering.
12. They are pursuing opportunities to vaccinate through government contract of underserved population of central valley California – happening as we speak.

 
 
Nuturell:
 

1. Anticipating orders from retail and hotel groups in the very near future.
2. Marvel Diagnostics (blowfish):
3. Meeting all milestones for FDA and EUA they had committed to
4. Interesting developments which Doug can’t talk about. Not only opportunities with covid but opportunities long after covid.
5. Involving a very well-known large institution which will be publicising the clinicals (NEXT WEEK HOPEFULLY)

 
 
Telehealth:
 

1. Pivoted early to move into telehealth
2. Telehealth currently worth about $61B USD. Research shows $560B by 2027. 27% CAGR! Huge growth.
3. Apparently 50% of all telehealth is all mental health currently. Medivolve is trying to do “telediagnostics”
4. Have 5 proprietary systems – will be delivered next week. They have number of peripherals which allows them to do video consultation. Digital scopes (eyes, ears, throat). Digital stethoscopes. Pulse oximeters. Scales. Blood pressure cuffs. All peripherals you see in a doctor’s office.
5. Doctors can utilize the techs and phlebotomists to order tests. They can take blood tests and send off to lab partners.              
6. MEDV is able to consolidate a lot of services at their sites or even mobile!
7. Same systems can be taken into long term care for patience wellness checks. Take them into areas where they cannot visit doctors.
8. Dr. Copeland is active in the sports medicine field. He’s a doctor for the Blue Jays and National Umpire’s Association. He says team doctors are available at the time of the games. Lots of injuries take place in training. If you not only think of pro teams, but TREMENDOUS demand in collegiate sports for this kind of service. 

 
 
AditxtScore/Aditxt Theraputics:
 

1. This is a long part in the webinar, and I urge you to watch the video yourself.
2. Starts around 11:45 mark.
3. I don’t have time to review this part

 
STOCK PRICE:
Lots of questions on this and Doug is addressing this.

1. Management is aware of the negative pressures of share price.
2. Shorting has been taking place
3. Management hasn’t seen “nefarious” activity beyond market behaviour
4. STRONGLY BELIEVE STOCK IS UNDERVALUED
5. WE strongly believe prime for growth
6. Consolidation of new base
7. FLUSHING OUT OF WEAK HANDS (yes – he did say this)
8. Awareness campaign has generated volume.
9. Best way to drive share price and growth is to focus execution of the business plan, pivot to telediagnostics, adding initiatives like Aditxt.
10. Best way to fight back on negative pressure is to expedite growth, pivot beyond covid, broaden offering and position HUGE growth in telehealth, telediagnostics and telemedicine. 
11. Reiterates $560B market in 2027.